

MYRIAD GENETICS, INC.

CASE OVERVIEW

Status: Investigating

Company Name: Myriad Genetics, Inc.

Ticker: MYGN

Related Attorneys: Thomas W. Elrod

Related Practices: Securities

On July 30, 2026, Myriad Genetics reported that its second-quarter revenue declined 11% year-over-year to 190.7 million and average revenue per test declined 9%. The Company reduced its full-year 2026 revenue guidance to \$770 to 790 million and revealed an \$11 million reduction in revenue due to changes in collection estimates for tests completed in prior periods. Additionally, Myriad reported that hereditary cancer testing revenue declined 13%, despite an 8% increase in volume, attributing the decline to lower reimbursement and unfavorable estimate changes associated primarily with first-quarter 2026 orders. Management stated that payer-generated revenue-cycle friction was “not new” and identified changing prior-authorization requirements, increased medical-record requests, and higher denial rates. Management acknowledged that the Company “should have engaged earlier and more directly with payers as conditions evolved” and that earlier intervention “could have reduced the downstream impact.”

On this news, Myriad’s stock price declined by \$2.51, or 47%, to close at \$2.86 on July 31, 2026.